Drug Profile
Research programme: phosphodiesterase 4 inhibitors - Tetra Discovery Partners
Alternative Names: PDE4 inhibitors - Tetra Discovery Partners; PDE4 modulators - Tetra Discovery Partners; PDE4B inhibitor; PDE4D inhibitor; Phosphodiesterase 4 modulators - Tetra Discovery PartnersLatest Information Update: 01 Dec 2016
Price :
*
At a glance
- Originator Tetra Discovery Partners
- Class Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Brain injuries; Schizophrenia
Highest Development Phases
- Preclinical Cognition disorders
- Research Brain injuries; Huntington's disease
- No development reported Depressive disorders; Mild cognitive impairment; Schizophrenia
Most Recent Events
- 29 Nov 2016 Tetra Discovery Partners receives a grant from National Institute of Mental Health for development in Depressive disorders
- 16 Jul 2016 No recent reports of development identified for research development in Depressive disorders in USA
- 16 Jul 2016 No recent reports of development identified for research development in Mild-cognitive-impairment in USA